Silence Therapeutics Files 6-K with Press Release
Ticker: SLNCF · Form: 6-K · Filed: Mar 13, 2024 · CIK: 1479615
| Field | Detail |
|---|---|
| Company | Silence Therapeutics PLC (SLNCF) |
| Form Type | 6-K |
| Filed Date | Mar 13, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, press-release, regulatory-update
TL;DR
Silence Therapeutics dropped a 6-K filing with a press release from Feb 23rd - check for news.
AI Summary
Silence Therapeutics plc filed a Form 6-K on March 13, 2024, to report a press release dated February 23, 2024. The press release, filed as Exhibit 99.1, likely contains significant company updates or announcements.
Why It Matters
This filing indicates Silence Therapeutics is providing updated information to the SEC, which could contain material news impacting investors.
Risk Assessment
Risk Level: medium — Form 6-K filings often contain material updates, but the specific content of the press release is not detailed here, requiring further investigation.
Key Numbers
- 001-39487 — SEC File Number (Identifies the specific SEC filing series for Silence Therapeutics plc.)
Key Players & Entities
- Silence Therapeutics plc (company) — Registrant
- 0001193125-24-066379 (filing_id) — Accession Number
- March 13, 2024 (date) — Filing Date
- February 23, 2024 (date) — Press Release Date
- Exhibit 99.1 (document) — Attached Press Release
FAQ
What is the specific content of the press release dated February 23, 2024, filed as Exhibit 99.1?
The provided text states that Exhibit 99.1 is a press release dated February 23, 2024, but does not detail its content beyond mentioning it was titled 'Silence Therapeutics Announces Positive Topline'.
What is the primary purpose of this Form 6-K filing?
The Form 6-K is a Report of Foreign Private Issuer filed pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, used to report material information that the company has made or is required to make public in its home country.
When was Silence Therapeutics plc incorporated or registered?
The filing indicates the company's state of incorporation is 'X0', but does not provide a specific date of incorporation.
What is the principal executive office address of Silence Therapeutics plc?
The principal executive offices are located at 72 Hammersmith Road, London W14 8TH, United Kingdom.
Does Silence Therapeutics plc file annual reports under Form 20-F?
Yes, the filing includes a checkmark indicating that the registrant files annual reports under cover of Form 20-F.
Filing Stats: 235 words · 1 min read · ~1 pages · Grade level 14.1 · Accepted 2024-03-13 07:10:55
Filing Documents
- d791816d6k.htm (6-K) — 9KB
- d791816dex991.htm (EX-99.1) — 10KB
- g791816g0313014215373.jpg (GRAPHIC) — 3KB
- 0001193125-24-066379.txt ( ) — 24KB
From the Filing
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2024 Commission File Number: 001-39487 Silence Therapeutics plc (Exact Name of Registrant as Specified in Its Charter) 72 Hammersmith Road London W14 8TH United Kingdom (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-FForm 40-F Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): Filed as Exhibit 99.1 to this Report on Form 6-K is a press release of Silence Therapeutics plc, dated February 23, 2024. EXHIBIT INDEX Exhibit No. Description 99.1 Press release, dated March 13, 2024, Silence Therapeutics Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Silence Therapeutics plc By: /s/ Craig Tooman Name: Craig Tooman Title: President and Chief Executive Officer Date: March 13, 2024